Multispecific binding agents against CD40 and CD137 in combination therapy of cancer

Patent Number: CN-117957253-A

Publication Year: 2024

Application Year: 2022

Priority Year: 2021

Jurisdictions: CN

Status: Pending

Inventors:

SAHIN UGUR BLUM JORDAN GARRIDO CASTRO PATRICIA NYWOOD MICHELLE GIESEKE FRIEDERIKE BECKMANN CARSTEN PAULMANN CLAUDIA KUZMANOV IVAN BRYE ESTHER CORNELIA WILHELMINA GUERRAND LARS NATHAN JOOST MUIK ALEXANDER DE KLEUK BART-JAN HIBBERT RICHARD SCHUURMAN JANINE LABRIEN ALAIN FRANCK FROHMEIER-KOPF SINA FU YALI ADAMS III HOMER BAJAJ GAURAV HIGGS BRANDON FERRECHT MARC SPIRES VANESSA

Applicants:

  1. Genmab (Denmark)
    2. [NORA names: Genmab; Private Research; Denmark; Europe, EU; Nordic; OECD]
  2. Debiotech (Switzerland)
    3. [NORA names: Switzerland; Europe, Non-EU; OECD]

Abstract

The present invention relates to such combination therapies: which uses a combination of a binding agent that binds to human CD40 and to human CD137 and a checkpoint inhibitor to reduce or prevent tumor progression or to treat cancer.

Patent Family Records (1)

Multispecific binding agents against CD40 and CD137 in combination therapy of cancer

Debiotech (Switzerland), Debiotech SA, Genmab (Denmark), Genmab AS SAHIN UGUR, BLUM JORDAN, GARRIDO CASTRO PATRICIA, (...more)

2024, CN-117957253-A

Data Provider: Digital Science

LINKS
+

External Systems

SUBJECTS
+

PATENT CATEGORIES
+

IPCR Classification

CPC Classification

[No Data Available]

METRICS
+

Citation Metrics

Times Cited in Patents: 0external link

References to Patents: [No Data Available]

References to Publications: 0external link